Will Russian Life Science Investment Dollars Be Coming the Way of Your Business? After capturing the attention of the global biotech community in 2011 with a combined investment of $94.5 million USD in Bind and Selecta Biosciences, RusNano has recently announced a partnership with Domain Associates for a $760 million USD life science investment initiative. Mark Sharp, Global Life Sciences Head of Spenglerfox will be hosting a global conference call with Robert Rosen – the Director General for both Bind and Selecta’s Bioscience’s Russian based operations. Robert played a pivotal role in the Bind and Selecta agreement with RusNano, and will provide intriguing insight into how the deal came about, how the new partnership is evolving, and where future opportunities may lay for organisations interested in this type of investment paradigm. The call is intended for Senior Leadership in Global Emerging Biotech/Medtceh Organisations, or Venture Capital/Private Equity professionals with a focus on life sciences investments.